New treatment strategies for hepatitis C infection

World Journal of Hepatology

Volumn 7, Issue 17, 2015, Pages 2100-2109

  Ermis, Fatih ^a   Tasci, Elif Senocak ^a  

^a DUZCE UNIVERSITY   (Turkey)

Author keywords

Direct acting antivirals; Eradication; Genotype; Hepatitis C virus infection; Interferon free; Treatment

Indexed keywords

EID: 84939208678     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v7.i17.2100     Document Type: Short Survey

References (76)

1. Wandeler G, Dufour JF, Bruggmann P, Rauch A. Hepatitis C: a changing epidemic. Swiss Med Wkly 2015; 145: w14093 [PMID:25658972 DOI: 10.4414/smw.2015.14093]
2. Chung RT, Baumert TF. Curing chronic hepatitis C--the arc of a medical triumph. N Engl J Med 2014; 370: 1576-1578 [PMID:24720678 DOI: 10.1056/NEJMp1400986]
3. Petta S, Macaluso FS, Craxì A. Cardiovascular diseases and HCV infection: a simple association or more? Gut 2014; 63: 369-375 [PMID: 24295849 DOI: 10.1136/gutjnl-2013-306102]
4. Kim do Y, Ahn SH, Han KH. Emerging therapies for hepatitis C. Gut Liver 2014; 8: 471-479 [PMID: 25228970 DOI: 10.5009/gnl14083]
5. Lim SG. Chronic hepatitis C genotype 1 treatment roadmap for resource constrained settings. World J Gastroenterol 2015; 21:1972-1981 [PMID: 25684966 DOI: 10.3748/wjg.v21.i6.1972]
6. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourlière M, Sulkowski MS, Wedemeyer H, Tam E, Desmond P, Jensen DM, Di Bisceglie AM, Varunok P, Hassanein T, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1604-1614 [PMID: 24720679 DOI: 10.1056/NEJMoa1401561]
7. Boccaccio V, Bruno S. Management of HCV patients with cirrhosis with direct acting antivirals. Liver Int 2014; 34 Suppl 1:38-45 [PMID: 24373077 DOI: 10.1111/liv.12391]
8. Alexopoulou A, Karayiannis P. Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals. Ann Gastroenterol 2015; 28: 55-65 [PMID: 25608803]
9. Poordad F, Dieterich D. Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. J Viral Hepat 2012; 19: 449-464 [PMID: 22676357 DOI: 10.1111/j.1365-2893.2012.01617.x]
10. Scheel TK, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med 2013; 19: 837-849 [PMID: 23836234 DOI: 10.1038/nm.3248]
11. Osinusi A, Meissner EG, Lee YJ, Bon D, Heytens L, Nelson A, Sneller M, Kohli A, Barrett L, Proschan M, Herrmann E, Shivakumar B, Gu W, Kwan R, Teferi G, Talwani R, Silk R, Kotb C, Wroblewski S, Fishbein D, Dewar R, Highbarger H, Zhang X, Kleiner D, Wood BJ, Chavez J, Symonds WT, Subramanian M, McHutchison J, Polis MA, Fauci AS, Masur H, Kottilil S. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 2013; 310: 804-811 [PMID: 23982366 DOI: 10.1001/jama.2013.109309]
12. Muir AJ. The rapid evolution of treatment strategies for hepatitis C. Am J Gastroenterol 2014; 109: 628-635; quiz 636 [PMID:24732866 DOI: 10.1038/ajg.2014.66]
13. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-1887 [PMID: 23607594 DOI: 10.1056/NEJMoa1214853]
14. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206 [PMID: 21449783 DOI: 10.1056/NEJMoa1010494]
15. Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, DeMicco M, Bernstein DE, Afdhal N, Vierling JM, Gordon SC, Anderson JK, Hyland RH, Dvory-Sobol H, An D, Hindes RG, Albanis E, Symonds WT, Berrey MM, Nelson DR, Jacobson IM. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013; 381: 2100-2107 [PMID: 23499440 DOI: 10.1016/S0140-6736(13)60247-0]
16. Sadler MD, Lee SS. Revolution in hepatitis C antiviral therapy. Br Med Bull 2015; 113: 31-44 [PMID: 25680808 DOI: 10.1093/bmb/ldv004]
17. Jacobson IM, Dore, GJ, Foster GR, Fried MW, Radu M, Rafalskiy VV, Moroz I, Craxì A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, Kalmeijer R, Beumont-Mauviel M. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype 1 infection in treatment-naïve patients: results from QUEST-1, a phase III trial. Presented at the 48th annual meeting of the European Association for the Study of the Liver, Amsterdam, The Netherlands, 2013:Abstract 1425
18. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 2002; 30: 883-891 [PMID: 12124305 DOI: 10.1124/dmd.30.8.883]
19. Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y, Janczewska E, Villamil F, Scott J, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Sinha R, Beumont-Mauviel M. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014; 384:414-426 [PMID: 24907224 DOI: 10.1016/S0140-6736(14)60538-9]
20. Hayashi N, Seto C, Kato M, Komada Y, Goto S. Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatmentnaïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroenterol 2014; 49: 138-147 [PMID:24005956 DOI: 10.1007/s00535-013-0875-1]
21. Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, Marcellin P, Manns M, Nikitin I, Poordad F, Sherman M, Zeuzem S, Scott J, Gilles L, Lenz O, Peeters M, Sekar V, De Smedt G, Beumont-Mauviel M. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013; 58:1918-1929 [PMID: 23907700 DOI: 10.1002/hep.26641]
22. Suzuki F, Toyota J, Ikeda K, Chayama K, Mochida S, Hayashi N, Ishikawa H, Miyagoshi H, Hu W, McPhee F, Hughes EA, Kumada H. A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection. Antivir Ther 2014; 19:491-499 [PMID: 24451122 DOI: 10.3851/IMP2730]
23. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, Schwartz H, Nelson DR, Everson GT, Eley T, Wind-Rotolo M, Huang SP, Gao M, Hernandez D, McPhee F, Sherman D, Hindes R, Symonds W, Pasquinelli C, Grasela DM. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211-221 [PMID: 24428467 DOI: 10.1056/NEJMoa1306218]
24. Miller MH, Agarwal K, Austin A, Brown A, Barclay ST, Dundas P, Dusheiko GM, Foster GR, Fox R, Hayes PC, Leen C, Millson C, Ryder SD, Tait J, Ustianowski A, Dillon JF. Review article:2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy. Aliment Pharmacol Ther 2014; 39:1363-1375 [PMID: 24754233 DOI: 10.1111/apt.12764]
25. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2014. J Hepatol 2014; 61: 373-395 [PMID: 24818984 DOI: 10.1016/j.jhep.2014.05]
26. AASLD/IDSA/IAS-USA. Recommendations for testing, managing, and treating hepatitis C. [Accessed on March 20, 2015]. Available from: URL: http://www.hcvguidelines.org 27 Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, Hindes RG, Berrey MM. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368: 34-44 [PMID: 23281974 DOI: 10.1056/NEJMoa1208953]
27. Lalezari JP, Nelson DR, Hyland RH, Lin M, Rossi SJ, Symonds WT, Rodriguez-Torres M, Lawitz EJ. Once daily sofosbuvir plus ribavirin for 12 and 24 weeks in treatment-naive patients with HCV infection: the QUANTUM study. J Hepatol 2013; 58: 346 [DOI: 10.1016/S0168-8278(13)60847-8]
28. Jacobson I, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, Sulkowski MS, DeJesus E, Pearlman B, Rabinovitz M, Gitlin N, Lim JK, Pockros PJ, Fevery B, Lambrecht T, Ouwerkerk-Mahadevan S, Callewaert K, Symonds WT, Picchio G, Lindsay K, Beumont-Mauviel M, Lawitz E. SVR Results of a Once-Daily Regimen of Simeprevir (TMC435) Plus Sofosbuvir (GS-7977) With or Without Ribavirin in Cirrhotic and non-Cirrhotic HCV Genotype 1 Treatment Naive and Prior Null Repsonder Patients: The COSMOS Study. Annual Meeting of the American Association for the Study of Liver Disease (AASLD). Washington DC, 2013: LB-3
29. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-1493 [PMID: 24725238 DOI: 10.1056/NEJMoa1316366]
30. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M, Rustgi V, Chojkier M, Herring R, Di Bisceglie AM, Pockros PJ, Subramanian GM, An D, Svarovskaia E, Hyland RH, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Pound D, Fried MW. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879-1888 [PMID: 24720702 DOI: 10.1056/NEJMoa1402355]
31. Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet 2015; 385: 1124-1135 [PMID: 25687730 DOI: 10.1016/S0140-6736(14)62401-6]
32. Waheed Y. Ledipasvir and sofosbuvir: Interferon free therapy for hepatitis C virus genotype 1 infection. World J Virol 2015; 4: 33-35 [PMID: 25674516 DOI: 10.5501/wjv.v4.i1.33]
33. Kohli A, Osinusi A, Sims Z, Nelson A, Meissner EG, Barrett LL, Bon D, Marti MM, Silk R, Kotb C, Gross C, Jolley TA, Sidharthan S, Petersen T, Townsend K, Egerson D, Kapoor R, Spurlin E, Sneller M, Proschan M, Herrmann E, Kwan R, Teferi G, Talwani R, Diaz G, Kleiner DE, Wood BJ, Chavez J, Abbott S, Symonds WT, Subramanian GM, Pang PS, McHutchison J, Polis MA, Fauci AS, Masur H, Kottilil S. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Lancet 2015; 385: 1107-1113 [PMID: 25591505 DOI: 10.1016/S0140-6736(14)61228-9]
34. Welzel TM, Dultz G, Zeuzem S. Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors. J Hepatol 2014; 61: S98-S107 [PMID: 25443350 DOI: 10.1016/j.jhep.2014.08.014]
35. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, Weiland O, Aguilar H, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1594-1603 [PMID: 24720703 DOI: 10.1056/NEJMoa1315722]
36. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, DeJesus E, Pearlman B, Rabinovitz M, Gitlin N, Lim JK, Pockros PJ, Scott JD, Fevery B, Lambrecht T, Ouwerkerk-Mahadevan S, Callewaert K, Symonds WT, Picchio G, Lindsay KL, Beumont M, Jacobson IM. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384: 1756-1765 [PMID: 25078309 DOI: 10.1016/S0140-6736(14)61036-9]
37. Vermehren J, Sarrazin C. The role of resistance in HCV treatment. Best Pract Res Clin Gastroenterol 2012; 26: 487-503 [PMID:23199507 DOI: 10.1016/j.bpg.2012.09.011]
38. Peter J, Nelson DR. Optimal interferon-free therapy in treatmentexperienced chronic hepatitis C patients. Liver Int 2015; 35 Suppl 1:65-70 [PMID: 25529089 DOI: 10.1111/liv.12718]
39. Zeuzem S, Berg T, Gane E, Ferenci P, Foster GR, Fried MW, Hezode C, Hirschfield GM, Jacobson I, Nikitin I, Pockros PJ, Poordad F, Scott J, Lenz O, Peeters M, Sekar V, De Smedt G, Sinha R, Beumont-Mauviel M. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology 2014; 146:430-41.e6 [PMID: 24184810 DOI: 10.1053/j. gastro.2013.10.058]
40. Forns X, Lawitz E, Zeuzem S, Gane E, Bronowicki JP, Andreone P, Horban A, Brown A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, Scott J, De La Rosa G, Kalmeijer R, Sinha R, Beumont-Mauviel M. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014; 146: 1669-79.e3 [PMID: 24602923 DOI: 10.1053/j.gastro.2014.02.051]
41. AASLD/IDSA/IAS-USA. Retreatment of persons in whom prior therapy has failed. [Accessed on March 20, 2015]. Available from:URL: http://www.hcvguidelines.org
42. Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A, Müllhaupt B, Horsmans Y, Weiland O, Reesink HW, Rodrigues L, Hu YB, Podsadecki T, Bernstein B. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 2014; 147: 359-365.e1 [PMID: 24818763 DOI: 10.1053/j.gastro.2014.04.045]
43. Dore GJ, Lawitz E, Hezode C, H'ezode C, Shafran S, Ramji A, Tatum H, Taliani G, Tran A, Brunetto M, Zaltron S, Strasser S, Weis N, Ghesquiere W, Lee S, Larrey D, Pol S, Harley H, George J, Fung S, L'edinghen V, Hagens P, Cohen D, Cooney E, Noviello S, Hughes E. Daclatasvir combined with peginterferon alfa-2A and ribavirin for 12 or 16 weeks in patients with HCV genotype 2 or 3 infection: COMMAND GT2/3 STUDY. J Hepatol 2013; 58:570-571 [DOI: 10.1016/S0168-8278(13)61417-8]
44. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, Schiff E, Al-Assi MT, Subramanian GM, An D, Lin M, McNally J, Brainard D, Symonds WT, McHutchison JG, Patel K, Feld J, Pianko S, Nelson DR. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368:1867-1877 [PMID: 23607593 DOI: 10.1056/NEJMoa1214854]
45. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, Illeperuma A, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Weiland O, Reesink HW, Ferenci P, Hézode C, Esteban R. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370: 1993-2001 [PMID:24795201 DOI: 10.1056/NEJMoa1316145]
46. Lawitz E, Poordad F, Brainard D, Hyland RH, An D, Symonds WT, McHutchison JG, Membreno FE. Sofosbuvir in combination with PegIFN and ribavirin for 12 weeks provides wigh SVR rates in HCV-infected genotype 2 or 3 treatment-experienced patients with and without compensated cirrhosis: results from the LONESTAR-2 study. Hepatology 2013; 58: 1380A
47. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, Illeperuma A, Svarovskaia ES, Brainard DM, Symonds WT, McHutchison JG, Weiland O, Reesink HW, Ferenci P, Hézode C, Esteban R. Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial. Hepatology 2013; 58: 733
48. Petta S, Craxì A. Current and future HCV therapy: do we still need other anti-HCV drugs? Liver Int 2015; 35 Suppl 1: 4-10 [PMID:25529081 DOI: 10.1111/liv.12714]
49. Nelson DR. All oral 12 week combination treatment with daclatasvir and sofosbuvir in patients infected with HCV genotype 3: ALLY-3 phase 3 study. 65th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA, USA, 2014: Abstract LB3
50. Hezode C, Marcellin P, Pol S, Hassanein T, Fleischer-Stepniewska K, Baykal T, Wang T, Lovell SS, Pilot-Matias T, Vilche RA. Results from the phase 2 PEARL-I study: interferon-free regimens of ABT-450/r ABT-267 with or without ribavirin in patients with HCV genotype 4 infection. Presented at the annual meeting of EASL. UK: London, 2013
51. Kapoor R, Kohli A, Sidharthan S, Sims Z, Petersen T, Osinusi A, Nelson AK, Silk R, Kotb C, Sugarman K, Lam BP, Pang PS, Subramanian M, McHutchison JG, Masur H, Kottilil S, Rustgi VK. Treatment of hepatitis C genotype 4 with ledipasvir and sofosbuvir for 12 weeks: results of the SYNERGY trial. American Association for the Study of Liver Diseases (AASLD) Liver Meeting. Boston, 2014: Abstract 240
52. Sulkowski MS, Rodriguez-Torres M, Lalezari JP, Fessel JW, Mounzer K, Shuhart M, Luetkemeyer A, Asmuth D, Gaggar A, Ni L, Svarovskaia E, Symonds B, McHutchison J, Naggie S, Dieterich D. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infection in patients co-infected with HIV (PHOTON-1). 64th Annual Meeting of the American Association for the Study of Liver Diseases. Washington, DC, USA, 2013: Abstr 212
53. Coppola N, Martini S, Pisaturo M, Sagnelli C, Filippini P, Sagnelli E. Treatment of chronic hepatitis C in patients with HIV/HCV coinfection. World J Virol 2015; 4: 1-12 [PMID: 25674512 DOI: 10.5501/wjv.v4.i1.1]
54. Rodriguez-Torres M. Sofosbuvir and peginterferon alfa-2a/ribavirin for treatment-naïve genotype 1-4 HCV infected patients who are HIV coinfected with HIV. San Francisco, CA, 2013
55. Dieterich D, Rockstroh JK, Orkin C, Gutiérrez F, Klein MB, Reynes J, Shukla U, Jenkins A, Lenz O, Ouwerkerk-Mahadevan S, Peeters M, De La Rosa G, Tambuyzer L, Jessner W. Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study. Clin Infect Dis 2014; 59: 1579-1587 [PMID: 25192745 DOI: 10.1093/cid/ciu675]
56. Osinusi A, Townsend K, Nelson A, Kohli A, Gross C, Polis MA, Pang PS, Symonds WT, Talwani R, Sajadi MM, Hogan J, Subramanian GM, McHutchison JG, Masur H, Kottilil S. Use of sofosbuvir/ledipasvir fixed dose combination for treatment of HCV genotype-1 in patients coinfected with HIV. Program and abstracts of the 49th Annual Meeting of the European Association for the Study of the Liver. London, England, Paper presented at: ID Week, 2013
57. Sulkowski MS, Naggie S, Lalezari J, Fessel WJ, Mounzer K, Shuhart M, Luetkemeyer AF, Asmuth D, Gaggar A, Ni L, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Rodriguez-Torres M, Dieterich D. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 2014; 312: 353-361 [PMID: 25038354 DOI: 10.1001/jama.2014.7734]
58. Egger D, Wölk B, Gosert R, Bianchi L, Blum HE, Moradpour D, Bienz K. Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J Virol 2002; 76: 5974-5984 [PMID: 12021330 DOI: 10.1128/jvi.76.12.5974-5984.2002]
59. Chen G, Ren H, Zhang N, Lennox W, Turpoff A, Paget S, Li C, Almstead N, Njoroge FG, Gu Z, Graci J, Jung SP, Colacino J, Lahser F, Zhao X, Weetall M, Nomeir A, Karp GM. 6-(Azaindol-2-yl)pyridine-3-sulfonamides as potent and selective inhibitors targeting hepatitis C virus NS4B. Bioorg Med Chem Lett 2015; 25:781-786 [PMID: 25613678 DOI: 10.1016/j.bmcl.2014.12.093]
60. Koch JO, Bartenschlager R. Modulation of hepatitis C virus NS5A hyperphosphorylation by nonstructural proteins NS3, NS4A, and NS4B. J Virol 1999; 73: 7138-7146 [PMID: 10438800]
61. David N, Yaffe Y, Hagoel L, Elazar M, Glenn JS, Hirschberg K, Sklan EH. The interaction between the hepatitis C proteins NS4B and NS5A is involved in viral replication. Virology 2015; 475:139-149 [PMID: 25462354 DOI: 10.1016/j.virol.2014.10.021]
62. Steinmann E, Penin F, Kallis S, Patel AH, Bartenschlager R, Pietschmann T. Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions. PLoS Pathog 2007; 3: e103 [PMID: 17658949 DOI: 10.1371/journal.ppat.0030103]
63. Luscombe CA, Huang Z, Murray MG, Miller M, Wilkinson J, Ewart GD. A novel Hepatitis C virus p7 ion channel inhibitor, BIT225, inhibits bovine viral diarrhea virus in vitro and shows synergism with recombinant interferon-alpha-2b and nucleoside analogues. Antiviral Res 2010; 86: 144-153 [PMID: 20156486 DOI: 10.1016/j.antiviral.2010.02.312]
64. Griffin SD, Beales LP, Clarke DS, Worsfold O, Evans SD, Jaeger J, Harris MP, Rowlands DJ. The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine. FEBS Lett 2003; 535: 34-38 [PMID: 12560074 DOI: 10.1016/s0014-5793(02)03851-6]
65. Du QS, Wang SQ, Chen D, Meng JZ, Huang RB. In depth analysis on the binding sites of adamantane derivatives in HCV (hepatitis C virus) p7 channel based on the NMR structure. PLoS One 2014; 9:e93613 [PMID: 24714586 DOI: 10.1371/journal.pone.0093613]
66. Deltenre P, Henrion J, Canva V, Dharancy S, Texier F, Louvet A, De Maeght S, Paris JC, Mathurin P. Evaluation of amantadine in chronic hepatitis C: a meta-analysis. J Hepatol 2004; 41: 462-473 [PMID: 15336450 DOI: 10.1016/j.jhep.2004.05.019]
67. Pavlovic D, Fischer W, Hussey M, Durantel D, Durantel S, Branza-Nichita N, Woodhouse S, Dwek RA, Zitzmann N. Long alkylchain iminosugars block the HCV p7 ion channel. Adv Exp Med Biol 2005; 564: 3-4 [PMID: 16400798 DOI: 10.1007/0-387-25515-x_2]
68. StGelais C, Tuthill TJ, Clarke DS, Rowlands DJ, Harris M, Griffin S. Inhibition of hepatitis C virus p7 membrane channels in a liposome-based assay system. Antiviral Res 2007; 76: 48-58 [PMID: 17574688 DOI: 10.1016/j.antiviral.2007.05.001]
69. McHutchison JG, Patel K, Pockros P, Nyberg L, Pianko S, Yu RZ, Dorr FA, Kwoh TJ. A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients. J Hepatol 2006; 44: 88-96 [PMID: 16274834 DOI: 10.1016/j.jhep.2005.09.009]
70. Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 2010; 50: 259-293 [PMID:20055705 DOI: 10.1146/annurev.pharmtox.010909.105654]
71. Lukavsky PJ. Structure and function of HCV IRES domains. Virus Res 2009; 139: 166-171 [PMID: 18638512 DOI: 10.1016/j.virusres.2008.06.004]
72. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005; 309: 1577-1581 [PMID: 16141076 DOI: 10.1126/science.1113329]
73. Elmén J, Lindow M, Schütz S, Lawrence M, Petri A, Obad S, Lindholm M, Hedtjärn M, Hansen HF, Berger U, Gullans S, Kearney P, Sarnow P, Straarup EM, Kauppinen S. LNA-mediated microRNA silencing in non-human primates. Nature 2008; 452:896-899 [PMID: 18368051 DOI: 10.1038/nature06783]
74. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, Kauppinen S, Ørum H. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010; 327: 198-201 [PMID: 19965718 DOI: 10.1126/science.1178178]
75. Laxton C, Brady K, Moschos S, Turnpenny P, Rawal J, Pryde DC, Sidders B, Corbau R, Pickford C, Murray EJ. Selection, optimization, and pharmacokinetic properties of a novel, potent antiviral locked nucleic acid-based antisense oligomer targeting hepatitis C virus internal ribosome entry site. Antimicrob Agents Chemother 2011; 55: 3105-3114 [PMID: 21502629 DOI: 10.1128/AAC.00222-11]
76. Bhat P, Shwetha S, Sharma DK, Joseph AP, Srinivasan N, Das S. The beta hairpin structure within ribosomal protein S5 mediates interplay between domains II and IV and regulates HCV IRES function. Nucleic Acids Res 2015; 43: 2888-2901 [PMID:25712089 DOI: 10.1093/nar/gkv110]